Janssen Pharmaceutical’s TREMFYA (guselkumab) succeeded in the phase 3 Discover programme by meeting the primary endpoints of American College of Rheumatology 20% improvement (ACR20) at week 24 in adult patients with active moderate to severe psoriatic arthritis (PsA).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,